Anastrozole - Breast cancer - chemoprevention

You are here : Home > Formulary Search > Anastrozole - Breast cancer - chemoprevention

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue

Formulations :

Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NICE

Restrictions / Comments :

Documentation

No records returned.

PAD Profile

ChemicalSubstance :

Anastrozole

Indication :

Breast cancer - chemoprevention

Group Name :

Keywords :

Brand Names Include :

Arimidex

Important Information :

Specialist initiation and prescribing for at least 1 month before any request is made for primary care prescribing.

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Anastrozole is used to treat.

Breast cancer

Other Drugs

Below are listed other drugs that are used to treat Breast cancer - chemoprevention.

Committee Recommendations (1)

07 Aug 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a formulary status for tamoxifen, anastrozole and raloxifene for chemoprevention in women at moderate or high risk of developing breast cancer for a duration of 5 years.

A BLUE (with specialist initiation) with 1 month prescribing by the specialist team following discussions with the patient about the risks and benefits of treatment.

Anastrozole can be used:

Postmenopausal WITHOUT severe osteoporosis

On occasion a patient may need time to consider treatment and may in those circumstances request that their GP prescribe. The GP will then need to consider if they have all the information from the specialist team in order to accept full clinical responsibility for prescribing for that patient.